Biologic drugs for conditions such as rheumatoid arthritis, cancer, rare blood disorders and other serious illnesses have radically changed patient outcomes. But these specialty drugs also represent an increasing portion of drug reimbursement costs.
Subsequent entry biologics (SEB) or biosimilars—new to the Canadian market—may offer potential cost savings for private drug plans. But should they be evaluated in the same way as generic brand-name synthetic drugs?
Read Biologics and biosimilars: A new complexity in the world of medicines, sponsored by Amgen, and find out how biologic, biosimilar and speciality drugs compare, how they are approved and what their use could mean to private drug plans.